Stock analysts at UBS Group initiated coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) in a research note issued to investors on Thursday, MarketBeat Ratings reports. The firm set a "buy" rating and a $37.00 price target on the stock. UBS Group's price target suggests a potential upside of 94.84% from the company's previous close.
Several other equities research analysts also recently weighed in on the stock. Jefferies Financial Group started coverage on shares of Syndax Pharmaceuticals in a research note on Friday, June 28th. They set a "buy" rating and a $37.00 target price on the stock. Barclays increased their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a research note on Thursday, August 15th. Citigroup boosted their target price on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a "buy" rating in a research note on Friday, August 16th. HC Wainwright increased their price target on Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a "buy" rating in a research report on Thursday, August 15th. Finally, Bank of America boosted their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a "buy" rating in a research report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $35.90.
Check Out Our Latest Report on Syndax Pharmaceuticals
Syndax Pharmaceuticals Stock Performance
Shares of Syndax Pharmaceuticals stock traded up $0.45 on Thursday, reaching $18.99. The company had a trading volume of 813,457 shares, compared to its average volume of 1,060,844. The firm's 50 day moving average price is $19.28 and its two-hundred day moving average price is $20.48. Syndax Pharmaceuticals has a 52-week low of $11.51 and a 52-week high of $25.34. The firm has a market cap of $1.61 billion, a PE ratio of -5.90 and a beta of 0.91.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.91) by $0.11. The firm had revenue of $3.50 million during the quarter. During the same quarter last year, the firm posted ($0.64) earnings per share. The firm's revenue for the quarter was up 3499999990.0% compared to the same quarter last year. As a group, sell-side analysts predict that Syndax Pharmaceuticals will post -3.66 EPS for the current year.
Institutional Trading of Syndax Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock worth $58,000 after purchasing an additional 541 shares in the last quarter. Sei Investments Co. increased its position in Syndax Pharmaceuticals by 2.5% during the first quarter. Sei Investments Co. now owns 40,463 shares of the company's stock worth $963,000 after buying an additional 991 shares during the period. California State Teachers Retirement System lifted its stake in Syndax Pharmaceuticals by 1.5% in the first quarter. California State Teachers Retirement System now owns 76,557 shares of the company's stock valued at $1,822,000 after buying an additional 1,150 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Syndax Pharmaceuticals in the second quarter valued at approximately $27,000. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Syndax Pharmaceuticals by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company's stock valued at $187,000 after acquiring an additional 1,312 shares during the period.
Syndax Pharmaceuticals Company Profile
(
Get Free Report)
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Read More
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
